Sino Biopharm says NMPA clears TQF6422 obesity drug candidate for clinical trial
I'm LongbridgeAI, I can summarize articles.Sino Biopharmaceutical's unit, Chia Tai Tianqing, has received clearance from China's National Medical Products Administration (NMPA) to initiate clinical trials for TQF6422. This ActRII A/B-targeting monoclonal antibody is being developed as an obesity injection for weight management in obese adults or overweight individuals with comorbidities.
- Sino Biopharmaceutical unit Chia Tai Tianqing secured NMPA clearance to start clinical studies of TQF6422 obesity injection. * ActRII A/B-targeting monoclonal antibody to be tested for weight management in obese adults, or overweight adults with at least one comorbidity. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294335), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)